Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC Ads Should Be Better, Not Banned, In Wake Of Vioxx, Ex-FDAer Pitts Says

Executive Summary

The response to the Vioxx withdrawal offers further evidence of the need for FDA and manufacturers to modify the "brief summary" requirement in direct-to-consumer ads, former Associate Commissioner for External Relations Peter Pitts said during a Nov. 10 Drug & Device Dialogue audio conference sponsored by F-D-C Reports and Polidais LLC

You may also be interested in...

Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer

The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers

Celebrex Long-Term Safety Monitoring Results Reassure FDA

Data from long-term Celebrex (celecoxib) post-marketing studies reassure FDA of the COX-2 inhibitor's safety, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said

Vioxx Withdrawal Fuels Criticism Of DTC; Liability Exposure May Be Test

The Vioxx withdrawal will prompt renewed debate over DTC advertising

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts